Guo GH, Xie YB, Zhang PJ, Jiang T. Blood index panel for gastric cancer detection. World J Gastrointest Surg 2022; 14(9): 1026-1036 [PMID: 36185564 DOI: 10.4240/wjgs.v14.i9.1026]
Corresponding Author of This Article
Tao Jiang, MD, Doctor, Medicine Innovation Research Division of Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. laoai2915@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Sep 27, 2022; 14(9): 1026-1036 Published online Sep 27, 2022. doi: 10.4240/wjgs.v14.i9.1026
Blood index panel for gastric cancer detection
Guang-Hong Guo, Yi-Bin Xie, Peng-Jun Zhang, Tao Jiang
Guang-Hong Guo, Department of Laboratory Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Yi-Bin Xie, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Peng-Jun Zhang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Interventional Therapy Department, Peking University Cancer Hospital and Institute, Beijing 100142, China
Tao Jiang, Medicine Innovation Research Division of Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Guo GH and Jiang T designed the study; Guo GH and Zhang PJ performed the research; Guo GH and Xie YB analyzed the date; Guo GH wrote the paper; Jiang T and Zhang PJ revised the manuscript for final submission; Guo GH and Xie YB contributed equally to this study; Zhang PJ and Jiang T are the co-corresponding authors; and all authors have read and agreed to the published version of the manuscript.
Supported byNational Key Research and Development Program of China, No. 2020YFC2002700; CAMS Initiative for Innovative Medicine, No. 2016-I2M-1-007; National Natural Science Foundation of China, No. 81972010.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of First Center of Chinese PLA General Hospital.
Informed consent statement: All study participants or their legal guardian provided written informed consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Jiang, MD, Doctor, Medicine Innovation Research Division of Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. laoai2915@163.com
Received: February 22, 2022 Peer-review started: February 22, 2022 First decision: April 13, 2022 Revised: April 13, 2022 Accepted: August 14, 2022 Article in press: August 14, 2022 Published online: September 27, 2022 Processing time: 212 Days and 3.9 Hours
Abstract
BACKGROUND
Gastric cancer is a common malignant tumor. Early detection and diagnosis are crucial for the prevention and treatment of gastric cancer.
AIM
To develop a blood index panel that may improve the diagnostic value for discriminating gastric cancer and gastric polyps.
METHODS
Thirteen tumor-related detection indices, 38 clinical biochemical indices and 10 cytokine indices were examined in 139 gastric cancer patients and 40 gastric polyp patients to build the model. An additional 68 gastric cancer patients and 22 gastric polyp patients were enrolled for validation. After area under the curve evaluation and univariate and multivariate analyses.
RESULTS
Five tumor-related detection indices, 12 clinical biochemical indices and 1 cytokine index showed significant differences between the gastric cancer and gastric polyp groups. Carbohydrate antigen (CA) 724, phosphorus (P) and ischemia-modified albumin (IMA) were included in the blood index panel, and the area under the curve (AUC) of the index panel was 0.829 (0.754, 0.905). After validation, the AUC was 0.811 (0.700, 0.923). Compared to the conventional index CA724, the blood index panel showed significantly increased diagnostic value.
CONCLUSION
We developed an index model that included CA724, P and IMA to discriminate the gastric cancer and gastric polyp groups, which may be a potential diagnostic method for clinical practice.
Core Tip: Early diagnosis and early treatment of gastric cancer is the key to improving the survival and cure rates of patients. Therefore, early detection and diagnosis are crucial for the prevention and treatment of gastric cancer. In this study, the we aimed to evaluate the diagnostic value of the blood index panel for gastric cancer.
